KR101954945B1 - 출혈 장애를 치료하기 위한 변형된 세르핀 - Google Patents

출혈 장애를 치료하기 위한 변형된 세르핀 Download PDF

Info

Publication number
KR101954945B1
KR101954945B1 KR1020167018756A KR20167018756A KR101954945B1 KR 101954945 B1 KR101954945 B1 KR 101954945B1 KR 1020167018756 A KR1020167018756 A KR 1020167018756A KR 20167018756 A KR20167018756 A KR 20167018756A KR 101954945 B1 KR101954945 B1 KR 101954945B1
Authority
KR
South Korea
Prior art keywords
leu
delete delete
ser
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167018756A
Other languages
English (en)
Korean (ko)
Other versions
KR20160092025A (ko
Inventor
제임스 앤드류 헌팅톤
스테파니 폴데르디즈크
트레버 베이글린
Original Assignee
캠브리지 엔터프라이즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캠브리지 엔터프라이즈 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Publication of KR20160092025A publication Critical patent/KR20160092025A/ko
Application granted granted Critical
Publication of KR101954945B1 publication Critical patent/KR101954945B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020167018756A 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀 Active KR101954945B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322091.8 2013-12-13
GBGB1322091.8A GB201322091D0 (en) 2013-12-13 2013-12-13 Modified serpins for the treatment of bleeding disorders
PCT/EP2014/077783 WO2015086854A1 (en) 2013-12-13 2014-12-15 Modified serpins for the treatment of bleeding disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197006015A Division KR102186924B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Publications (2)

Publication Number Publication Date
KR20160092025A KR20160092025A (ko) 2016-08-03
KR101954945B1 true KR101954945B1 (ko) 2019-03-07

Family

ID=50030900

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167018756A Active KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀
KR1020197006015A Active KR102186924B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197006015A Active KR102186924B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Country Status (25)

Country Link
US (2) US9982035B2 (https=)
EP (2) EP3434689A1 (https=)
JP (2) JP6431541B2 (https=)
KR (2) KR101954945B1 (https=)
CN (2) CN110330563B (https=)
AU (2) AU2014363359B2 (https=)
CA (1) CA2933508C (https=)
CY (1) CY1121267T1 (https=)
DK (1) DK3080157T3 (https=)
EA (1) EA034050B1 (https=)
ES (1) ES2704058T3 (https=)
GB (1) GB201322091D0 (https=)
HR (1) HRP20182138T1 (https=)
HU (1) HUE042763T2 (https=)
IL (2) IL246180B (https=)
LT (1) LT3080157T (https=)
MX (1) MX357941B (https=)
NZ (1) NZ721918A (https=)
PL (1) PL3080157T3 (https=)
PT (1) PT3080157T (https=)
RS (1) RS58191B1 (https=)
SI (1) SI3080157T1 (https=)
SM (1) SMT201900016T1 (https=)
TR (1) TR201819781T4 (https=)
WO (1) WO2015086854A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2018154044A1 (en) * 2017-02-23 2018-08-30 Umc Utrecht Holding B.V. Modified serpins for the treatment of bradykinin-mediated disease
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
RU2663464C1 (ru) * 2018-02-26 2018-08-06 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Комбинаторная терапия для лечения геморрагического шока
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN110051830A (zh) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 一种protease nexin II\KPI蛋白突变体的应用
EP4326869A4 (en) * 2021-04-20 2025-12-10 Univ Of Louisville RECOMBINATING MICRO-NECK
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium
EP4707391A1 (en) * 2024-09-10 2026-03-11 e-therapeutics PLC Nucleic acid compounds for zpi inhibition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
DE3705745A1 (de) 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
IE902276A1 (en) 1989-06-26 1991-01-16 Akzo Nv Serpin variants
US6566493B1 (en) 1996-11-19 2003-05-20 The University Of Vermont Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
JP2002010783A (ja) 2000-06-29 2002-01-15 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
JP2003093063A (ja) 2001-09-20 2003-04-02 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
WO2003039585A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2504365T3 (es) 2002-12-05 2014-10-08 Zz Biotech L.L.C. La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
US8106002B2 (en) 2005-04-18 2012-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising protein C inhibitor
US8333076B2 (en) * 2005-12-15 2012-12-18 Gulfstream Aerospace Corporation Isentropic compression inlet for supersonic aircraft
SG175602A1 (en) * 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
WO2008059043A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2008059009A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
JP2010533684A (ja) 2007-07-20 2010-10-28 ユニベルシテ パリ サッド １１ 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用
GB0714649D0 (en) 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
WO2009055669A2 (en) 2007-10-26 2009-04-30 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein c
EP2055783A1 (en) * 2007-10-30 2009-05-06 VIB vzw Insect inhibiting plant serpin mutants
CN101965409A (zh) 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
CN101977626A (zh) * 2008-01-21 2011-02-16 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
WO2010081878A1 (en) 2009-01-16 2010-07-22 Universite Paris-Sud Xi Mutated antithrombins, a process for preparing the same and their use as drugs
JP5727459B2 (ja) * 2009-04-22 2015-06-03 アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
US8557961B2 (en) * 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2996713B1 (en) 2013-05-15 2019-10-02 Mor Research Applications Ltd. Compositions and methods for treating post-operative complications of cardiopulmonary surgery
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2018154044A1 (en) * 2017-02-23 2018-08-30 Umc Utrecht Holding B.V. Modified serpins for the treatment of bradykinin-mediated disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Bio.l Chem. (2009), Vol 284, No.51, pp35652-35682.*
Journal of Biological Chemistry, Vol. 277, No. 33, pp29927-29935(2002)

Also Published As

Publication number Publication date
TR201819781T4 (tr) 2019-01-21
EA034050B1 (ru) 2019-12-23
ES2704058T3 (es) 2019-03-14
AU2014363359B2 (en) 2019-01-03
CY1121267T1 (el) 2020-05-29
WO2015086854A1 (en) 2015-06-18
JP6723319B2 (ja) 2020-07-15
JP2019037242A (ja) 2019-03-14
KR20160092025A (ko) 2016-08-03
US20160311887A1 (en) 2016-10-27
HRP20182138T1 (hr) 2019-02-08
EP3080157B1 (en) 2018-10-03
MX357941B (es) 2018-07-31
PL3080157T3 (pl) 2019-03-29
US20180273610A1 (en) 2018-09-27
CA2933508C (en) 2021-04-06
JP6431541B2 (ja) 2018-11-28
HUE042763T2 (hu) 2019-07-29
LT3080157T (lt) 2018-12-10
US9982035B2 (en) 2018-05-29
PT3080157T (pt) 2019-01-11
CA2933508A1 (en) 2015-06-18
AU2014363359A1 (en) 2016-07-21
GB201322091D0 (en) 2014-01-29
BR112016013591A2 (pt) 2017-10-03
NZ721918A (en) 2019-12-20
US10351619B2 (en) 2019-07-16
SMT201900016T1 (it) 2019-02-28
CN105992771A (zh) 2016-10-05
CN110330563B (zh) 2024-03-29
RS58191B1 (sr) 2019-03-29
SI3080157T1 (sl) 2018-12-31
KR102186924B1 (ko) 2020-12-04
CN110330563A (zh) 2019-10-15
JP2017505114A (ja) 2017-02-16
EP3434689A1 (en) 2019-01-30
DK3080157T3 (en) 2018-12-17
IL246180A0 (en) 2016-07-31
CN105992771B (zh) 2019-08-23
EA201691235A1 (ru) 2016-12-30
AU2018279054A1 (en) 2019-01-17
EP3080157A1 (en) 2016-10-19
KR20190022945A (ko) 2019-03-06
IL246180B (en) 2018-11-29
MX2016007711A (es) 2016-12-09
IL262879A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
KR101954945B1 (ko) 출혈 장애를 치료하기 위한 변형된 세르핀
JP7187505B2 (ja) 長時間作用型凝固因子およびその製造方法
JP2013531651A (ja) 線溶亢進を伴う凝固障害の処置
WO2023245335A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
JP2019516347A (ja) 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド
BR112016013591B1 (pt) Serpina modificada, célula recombinante que expressa a serpina, composição farmacêutica compreendendo a serpina e uso da serpina modificada para o tratamento ou prevenção de hemorragia ou para promoção de hemostasia
HK1229344B (en) Modified serpins for the treatment of bleeding disorders
HK1229344A1 (en) Modified serpins for the treatment of bleeding disorders
KR102597725B1 (ko) 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법
CN104395465A (zh) 表现出外位点介导的超级活性的FVIIa-sTF复合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8